A U.S. district court held that claims of US Patent No. 11,634,752—owned by Scale Biosciences and asserted against Parse Biosciences—are invalid for lack of written description and enablement. The decision arose in litigation over split‑pool barcoding library prep methods used in instrument‑free single‑cell sequencing workflows. Parse successfully challenged the patent as insufficiently described, marking another legal setback for Scale and its acquirer, 10x Genomics, in ongoing single‑cell platform disputes.